UNSPSC 51111602: Cytarabine

This classification denotes an antimetabolite, antineoplastic, antiviral agent, and immunosuppressive agent with the molecular formula C9H13N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04079A1RDZ, chemically known as 4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine but generally known as cytarabine, which bears US NIH Compound Identifier 596. European Medicines Agency schedules Cytarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06880MIG.

UNSPSC 51111602 Cytarabine is a Commodity code naming a chemotherapy agent that state and local governments procure primarily through health systems, correctional medical programs, and public hospital networks. The drug is used in acute leukemia treatment protocols and appears in procurement activity from state departments of corrections, county health authorities, municipal hospital systems, and independent healthcare districts. Purchasing occurs through both traditional competitive solicitations and standing cooperative purchasing agreements that allow healthcare entities to draw supply at negotiated rates. Orders typically reflect clinical demand patterns rather than project-based procurement; state and local health buyers source cytarabine through pharmaceutical distributors or directly from manufacturers, often bundling the purchase with broader oncology-drug contracts that cover multiple chemotherapy agents.

The source material provided contains no recent state or local contract opportunities under this code, limiting current visibility into active solicitation activity, issuing-body patterns, or geographic concentration. Without documented RFPs, RFQs, or ITBs in the recent-opportunities record, assessment of current procurement momentum, pricing trends, or contract award cycles for cytarabine across state and local jurisdictions is not supported by the available data.